Abstract
The objectives of this study were to assess the costs of psoriatic arthritis (PsA) in Hungary and to identify key cost drivers among demographic and clinical variables and to compare cost-of-illness of PsA and rheumatoid arthritis (RA). Cross-sectional retrospective survey of 183 consecutive patients from eight rheumatology centres was conducted. Mean direct medical, direct non medical, indirect and total costs were 1,876, 794, 2,904 and 5,574 euros/patient/year, respectively. Total costs were in significant linear relationship with health assessment questionnaire score and psoriatic area severity index. Costs of RA were higher in all domains than of PsA. Our study was the first from the Eastern European region that provides cost-of-illness data on PsA. Our study revealed that functional status and severity of skin symptoms were the key cost drivers. The costs of PsA in Hungary were lower than in the high-income European countries.
Similar content being viewed by others
References
Kobelt G, Jonsson B (2008) The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur J Health Econ 8(Suppl 2):95–106. doi:10.1007/s10198-007-0091-0
Ackermann C, Kavanaugh A (2008) Economic burden of psoriatic arthritis. Pharmacoeconomics 26:121–129
Javitz HS, Ward MM, Farber E, Nail L, Vallow SG (2002) The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 46:850–860. doi:10.1067/mjd.2002.119669
Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A, German Collaborative Arthritis C (2006) Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65:1175–1183. doi:10.1136/ard.2005.046367
Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A (1997) Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 36:551–559. doi:10.1093/rheumatology/36.5.551
McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ (2004) Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 63:162–169. doi:10.1136/ard.2003.006296
Lovas K, Koó É, Whalley D, Meads D, Kaló Z, McKenna SP (2002) Az arthritis psoriaticában szenvedő betegeknek kidolgozott életminőség-kérdőív magyarországi adaptációja. LAM 12:389–395
Bruce B, Fries JF (2003) The stanford health assessment questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 30:167–178
Pentek M, Szekanecz Z, Czirjak L, Poor G, Rojkovich B, Polgar A, Genti G, Kiss CG, Sandor Z, Majer I, Brodszky V, Gulacsi L (2008) Impact of disease progression on health status, quality of life and costs in rheumatoid arthritis in Hungary. Orv Hetil 149:733–741. doi:10.1556/OH.2008.28294
Péntek M, Kobelt G, Czirjak L, Szekanecz Z, Rojkovich B, Polgar A, Genti G, Kiss CG, Brodszky V, Majer I, Gulacsi L (2007) Costs of rheumatoid arthritis in Hungary. J Rheumatol 34:1437
Wallenius M, Skomsvoll JF, Koldingsnes W, Rodevand E, Mikkelsen K, Kaufmann C, Kvien TK (2008) Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis. doi:10.1080/03009740802400594
Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, Reynolds A, Emery P (2006) Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 45:1029–1038. doi:10.1093/rheumatology/kel147
Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ (2007) The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology (Oxford) 46:1729–1735. doi:10.1093/rheumatology/kem221
Zink A, Thiele K, Huscher D, Listing J, Sieper J, Krause A, Gromnica-Ihle E, von Hinueber U, Wassenberg S, Genth E, Schneider M (2006) Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 33:86–90
Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Cutro MS, Mathieu A, Matucci-Cerinic M, Pappone N, Punzi L, Scarpa R, Mantovani LG (2008) The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) 47:1664–1670. doi:10.1093/rheumatology/ken320
Acknowledgments
This study was supported by an unrestricted grant from Wyeth Hungary and The Centre for Public Affairs Studies Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brodszky, V., Bálint, P., Géher, P. et al. Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatol Int 30, 199–205 (2009). https://doi.org/10.1007/s00296-009-0936-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-0936-1